Form 4: Avidity Biosciences Director Noreen Henig Granted Equity Awards

Avidity Biosciences, Inc. Director Noreen Henig was granted 6,692 restricted stock units and options to purchase 10,034 shares of common stock, aligning her interests with shareholders.

Summary

• Noreen Henig, a Director of Avidity Biosciences, Inc. (RNA), acquired 6,692 shares of common stock in the form of Restricted Stock Units (RSUs) on June 10, 2025.
• Each RSU represents a contingent right to receive one share of the Issuer's common stock, granted at a price of $0.
• These RSUs are set to vest in full on the earlier of June 10, 2026, or the Issuer's 2026 annual meeting of stockholders, contingent upon Ms. Henig's continuous service.
• Additionally, Ms. Henig was granted stock options to acquire 10,034 shares of common stock on June 10, 2025, with an exercise price of $33.62 per share.
• These stock options also vest in full on the earlier of June 10, 2026, or the Issuer's 2026 annual meeting of stockholders, subject to her continuous service.
• The stock options have an expiration date of June 09, 2035.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it indicates standard compensation practices for a director, aligning their interests with shareholders, which is generally viewed favorably. It does not, however, provide new operational or financial performance insights.

Positives

• The grant of restricted stock units and stock options to Director Noreen Henig aligns her interests with those of the company's shareholders.
• Equity compensation is a standard practice for retaining and incentivizing key personnel, including directors.

Risks

• The vesting of both RSUs and stock options is contingent upon Ms. Henig's continuous service to the Issuer through the specified vesting date, meaning the awards could be forfeited if service ceases prematurely.

Future Outlook

This Form 4 filing primarily details an insider equity grant and does not contain forward-looking statements or guidance regarding the company's financial performance or strategic outlook.

Industry Context

The granting of equity awards, such as restricted stock units and stock options, to directors is a common practice across the biotechnology and pharmaceutical industries to attract, retain, and incentivize experienced board members, aligning their long-term interests with company performance and shareholder value.

Comparison to Industry Standards

• The structure of equity compensation, including RSUs and stock options with service-based vesting, is consistent with typical compensation packages for non-employee directors in the biotechnology sector.
• The vesting schedule tied to continuous service and a future annual meeting is a standard mechanism to ensure director commitment and long-term alignment.

Related Party Transactions

• The transaction involves the grant of equity awards to a director, which is a form of related party transaction intended as compensation.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's financial interests with shareholder value creation, as the value of the awards is tied to the company's stock performance.
• Employees: While not directly impacting general employees, the compensation structure for directors can reflect broader company policies on incentivizing key personnel.

Next Steps

• The RSUs and stock options are expected to vest on the earlier of June 10, 2026, or the Issuer's 2026 annual meeting of stockholders, subject to continuous service.

Key Dates

Keywords

Avidity Biosciences, RNA, Form 4, SEC filing, insider transaction, restricted stock units, RSUs, stock options, equity grant, director compensation, beneficial ownership, vesting